Evaluating patient responses to omalizumab in solar urticaria
- 19 October 2018
- journal article
- letter
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 35 (1) , 57-65
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Handicapped Research
This publication has 9 references indexed in Scilit:
- Solar urticaria in 145 patients: Assessment of action spectra and impact on quality of life in adults and childrenPhotodermatology, Photoimmunology & Photomedicine, 2018
- Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidenceJournal of Allergy and Clinical Immunology, 2018
- Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric studyJournal of the American Academy of Dermatology, 2016
- The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticariaJournal of Allergy and Clinical Immunology, 2015
- The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and updateAllergy, 2014
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Partial improvement of solar urticaria after omalizumabJournal of Allergy and Clinical Immunology, 2010
- How to assess disease activity in patients with chronic urticaria?Allergy, 2008
- A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU‐Q2oL)Allergy, 2005